Abstract:BACKGROUND & OBJECTIVE:The manifestations of old acute myelogenous (AML) patients have their special biological and clinical characteristics, with lower response rate to therapy and shorter survival time. This study was to investigate the prognostic factors of elderly patients with AML retrospectively. METHODS:77 patients aged> or =60 years with AML from 1994 to 2005 were admitted to our study and all the possible prognostic factors were analyzed with Kaplan-Meier survival analysis. The significant factors were further analyzed by Cox proportional hazard model analysis. RESULTS:Seventy-two patients were evaluated. The patients aged 60-70 (median survival time was 350 days) had significantly longer survival time than those aged more than 70 (median survival time is 60 days)(P<0.001), which their CR ratios were 71.4% and 29.4% (P=0.001). The patients with performance status 0 or 1 (median survival time was 402 days) had significantly longer survival time than those with performance status 2, 3 or 4 (median survival time was 31 days)(P<0.001), which their CR ratios were 75% and 15% (P<0.001). The patients with primary AML (median survival time was 98 days) had significantly longer survival time than those with secondary AML (median survival time was 32 days)(P=0.007), which their CR ratios were 50% and 0% (P=0.023). The patients treated with sub-standard dosage of anthracycline (median survival time was 293 days) had significantly longer survival time than those treated with reduced dosage of anthracycline (median survival time was 35 days)(P=0.006), which their CR ratios were 63.6% and 33.3% (P=0.02). The patients with bone marrow blast cell ratio< or =50% (median survival time was 98 days ) had significantly longer survival time than those with bone marrow blast cell ratio >50% (median survival time was 55 days)(P=0.006). The patients with favorable karyotype (median survival time was 293 days) had significantly longer survival time than those with unfavorable or normal karyotype (median survival time was 31 days)(P=0.005). The patients without CD34 expression (median survival time was 201 days) had significantly longer survival time than those with CD34 expression(median survival time was 36 days)(P<0.001). The patients with the peripheral blood white blood cell count (PBWBC)>10x10(9)/L (50%) had significantly higher CR ratio than those with PBWBC< or =10x10(9)/L (25%)(P=0.043). The patients received chemotherapy (50%) had significantly higher CR ratio than those received supportive therapy (0%)(P=0.001). In the stepwise COX proportional hazard regression model, all the seven factors related to OS remained independent and significant. CONCLUSIONS:Factors, including age >70, PS 2 to 4, percentage of blasts in bone marrow >50%, secondary AML, unfavorable karyotype, expression of CD34, lower dosage.

Acute leukemia in the elderly:clinical analysis of 340 cases

Aging and Comprehensive Molecular Profiling in Acute Myeloid Leukemia.

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

Factors Affecting Early Death and Survival of Patients with Acute Promyelocytic Leukemia Treated with ATRA-Based Therapy Regimens

Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia]

[Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia].

Analysis of Clinical Characteristics and Prognostic Factors in Elderly Patients with Acute Myeloid Leukemia

Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

Analysis of Characteristics and Clinical Effectiveness of Acute Myeloid Leukemia in the Elderly

Clinical and prognostic features of acute promyelocytic leukemia in the elderly

[Clinical Characteristics and Efficacy Analysis for Patients over 55 Years of Age with Acute Lymphoblastic Leukemia].

[Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].

[Clinical Characteristics and Prognosis of 84 Elderly Patients with Acute Myeloid Leukemia].

Individual Treatment of Acute Myelogenous Leukemia in Elderly Patients

Efficacy of different remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia

Cytogenetic Risk and Hemocyte Account for the Age-Related Poor Prognosis in Adult Acute Myeloid Leukemia Patients

ANALYSIS OF THREAPY EFFECT AND PROGNOSIS OF ACUTE MYELOGENOUS LEUKEMIA IN THE ≥70 PATIENTS

Clinical and Prognostic Analysis of Adult Acute Lymphoblastic Leukemia

Research on constituent ratios of subtypes in different age groups of 305 acute leukemia patients

[Analysis of Factors Influencing Overall Survival and Prognosis of AML Patients Over 50 Years Old]

Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions